Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,626 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03145077Recruiting
MRI test to diagnose jaw bone damage after head and neck radiation
This study uses special MRI scans with contrast to better detect osteoradionecrosis (jaw bone injury) after radiation for head and neck cancer. If you qualify, the scans may help your team diagnose problems earlier and choose the right next treatment.
Houston, TexasAges 18 years+ - NCT03150576RecruitingPhase 2/Phase 3
Before-surgery treatment for triple-negative or BRCA breast cancer
This trial tests an “at-the-source” medicine given before surgery to shrink triple-negative and/or BRCA-related breast cancer. It may help doctors see whether it improves tumor response and reduces cancer spread at surgery time.
Cambridge, CambridgeshireAges 16–70 - NCT03151629Recruiting
Registry for men with advanced prostate cancer
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
Birmingham, AlabamaAges 21 years+ - NCT03201861RecruitingPhase 3
Cisplatin added after surgery for high-risk breast cancer
This trial checks whether adding cisplatin to standard chemotherapy after surgery helps women with high-risk early-stage breast cancer lower the chance of the cancer coming back. You would be followed to see how well treatment works and whether it is tolerated.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+ - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT03591276RecruitingPhase 1/Phase 2
Doxorubicin plus pembrolizumab for hormone-resistant breast cancer
This Phase 1b/2 trial tests a combination of pegylated liposomal doxorubicin and pembrolizumab for breast cancer that no longer responds to hormone treatment. It aims to see how well the combination works and how safely it can be given to patients with advanced disease.
JerusalemAges 18 years+ - NCT03606967RecruitingPhase 2
Individualized vaccine added to standard treatment for metastatic triple-negative breast cancer
This Phase 2 trial tests whether adding a personalized cancer vaccine to durvalumab (an immunotherapy), tremelimumab (another immunotherapy), and chemotherapy can improve outcomes for people with metastatic triple-negative breast cancer. It may help your immune system recognize your specific tumor features.
Orange, CaliforniaAges 18 years+ - NCT03608631RecruitingPhase 1/Phase 2
Exosome treatment for KRAS-mutated metastatic pancreatic cancer
This Phase 1/2 study tests an investigational treatment made from “exosomes” for people with metastatic pancreatic cancer that has a specific KRAS mutation (KRAS G12D). It aims to see if this treatment can control the cancer and is safe for patients whose cancer has grown or stayed the same after prior chemotherapy.
Houston, TexasAges 18 years+ - NCT03675893RecruitingPhase 2
Test abemaciclib plus letrozole with or without extra drugs
This Phase 2 study tests whether adding medicines to standard hormone therapy (letrozole) can control endometrial cancer that has come back, spread, or stopped responding to usual treatments. It also explores whether extra drugs (metformin or gedatolisib) improve results for certain patient groups.
Boston, MassachusettsAges 18 years+ - NCT03686124RecruitingPhase 1/Phase 2
Tested immune therapy for certain HLA-A2 positive solid tumors
This trial studies an immune-based cancer treatment (IMA203/IMA203CD8) either alone or with nivolumab in people whose solid tumors have come back or will not respond to standard care. It may help by training the immune system to recognize and attack tumor cells that match the trial’s test requirements.
Stanford, CaliforniaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT03786796RecruitingPhase 2
Olaparib for metastatic kidney cancer with specific DNA repair gene changes
This trial tests olaparib (a pill medicine) in people with kidney cancer that has spread and specific DNA “repair” gene mutations. The goal is to see whether this targeted treatment can slow the cancer or help it respond better after prior immunotherapy or blood-vessel–blocking therapy.
Baltimore, MarylandAges 18–120 - NCT03803553RecruitingPhase 3
Testing blood tumor DNA treatment after stage III colon surgery
This trial studies how to find tiny hidden cancer cells after stage III colon cancer surgery using a blood test. If the blood test shows tumor DNA, you may get additional treatment to lower the chance of cancer coming back.
Boston, MassachusettsAges 18 years+ - NCT03815890RecruitingPhase 2
Pre-surgery nivolumab for certain types of breast cancer
This trial tests whether giving nivolumab before surgery (neoadjuvant treatment) can improve outcomes for people with certain resectable breast cancers. It focuses on tumor types linked to immune activity (like triple-negative and specific lab markers).
AmsterdamAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune conditions
This Phase 1 study tests nivolumab, an immunotherapy “anti-cancer accelerator,” in people with advanced cancer who also have an autoimmune disorder. It aims to see if nivolumab can be given safely and whether it may help shrink or control cancer.
Birmingham, AlabamaAges 18 years+ - NCT03819101RecruitingPhase 3
Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
OlomoucAges 18 years+ - NCT03821246RecruitingPhase 2
Atezolizumab and other drugs before prostate surgery for high-risk cancer
This Phase 2 trial tests whether giving immunotherapy (atezolizumab) plus another drug before surgery can shrink or control high-risk localized prostate cancer. The goal is to improve outcomes by treating the cancer early, before radical prostatectomy.
San Francisco, CaliforniaAges 18 years+ - NCT03844256RecruitingPhase 1/Phase 2
Bladder-sparing chemo-radiation plus immunotherapy for bladder cancer
This study tests whether adding immunotherapy drugs (nivolumab alone or nivolumab plus ipilimumab) to standard chemo-radiation can control muscle-invasive bladder cancer while helping people keep their bladder. It aims to find a safer, effective curative treatment for people who want to avoid bladder removal (cystectomy).
Amsterdam, North HollandAges 18 years+ - NCT07702708Recruiting
AI predicts chemotherapy response in HR+/HER2- breast cancer
This trial uses AI to analyze your pre-treatment MRI and predict how well your tumor will respond to chemotherapy before surgery. It is for people with HR+/HER2- breast cancer who need chemo before their operation.
Fuzhou, FujianAges 18 years+ - NCT06592924RecruitingPhase 3
Adding chemo to hormone therapy for prostate cancer with slow PSA drop
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
Anchorage, AlaskaAges 18 years+ - NCT05451004RecruitingPhase 3
SPECT-CT test to target neck radiation on one side
This study tests whether using a special scan (SPECT-CT) can guide radiation treatment to only the safer/needed side of the neck in people with a one-sided oropharyngeal cancer. It aims to keep cancer control while potentially reducing side effects from unnecessary radiation.
Corona, CaliforniaAges 18 years+ - NCT06205485RecruitingPhase 3
Chemotherapy and surgery vs chemoradiation for rectal cancer
This trial compares two approaches for early-stage rectal cancer: chemotherapy plus local surgery versus standard chemoradiotherapy. It aims to see if less intensive treatment can work just as well, reducing side effects.
Phoenix, ArizonaAges 18 years+ - NCT07214987RecruitingPhase 2
PDT with immunotherapy and chemo for head and neck cancer
This trial tests a combination of an immunotherapy drug (toripalimab) and two chemotherapy drugs (cisplatin and docetaxel) as a first treatment before surgery or radiation for advanced head and neck cancers. It may help shrink tumors that can't be easily treated with standard therapy.
Boston, MassachusettsAges 18 years+
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,626 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.